Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + HX008 in Advanced Penile Squamous Cell Carcinoma
NCT07054307Phase 1Recruiting
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of becotatug vedotin and pucotenlimab in penile squamous cell carcinoma (PSCC). Primary endpoint: Objective Response Rate at 12 weeks. Started Feb 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07054307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054307.